117 related articles for article (PubMed ID: 38513324)
1. One-step synthesis of diaryloxadiazoles as potent inhibitors of BCRP.
Yi W; Tran-Nguyen VK; Boumendjel A
Future Med Chem; 2024 Apr; 16(8):723-35. PubMed ID: 38573062
[No Abstract] [Full Text] [Related]
2. Updated chemical scaffolds of ABCG2 inhibitors and their structure-inhibition relationships for future development.
Moinul M; Amin SA; Jha T; Gayen S
Eur J Med Chem; 2022 Nov; 241():114628. PubMed ID: 35944339
[TBL] [Abstract][Full Text] [Related]
3. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
Doyle L; Ross DD
Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
[TBL] [Abstract][Full Text] [Related]
4. Magnolol derivatives as specific and noncytotoxic inhibitors of breast cancer resistance protein (BCRP/ABCG2).
da Silva Zanzarini I; Henrique Kita D; Scheiffer G; Karoline Dos Santos K; de Paula Dutra J; Augusto Pastore M; Gomes de Moraes Rego F; Picheth G; Ambudkar SV; Pulvirenti L; Cardullo N; Rotuno Moure V; Muccilli V; Tringali C; Valdameri G
Bioorg Chem; 2024 May; 146():107283. PubMed ID: 38513324
[TBL] [Abstract][Full Text] [Related]
5. Mechanistic basis of breast cancer resistance protein inhibition by new indeno[1,2-b]indoles.
Kita DH; Guragossian N; Zattoni IF; Moure VR; Rego FGM; Lusvarghi S; Moulenat T; Belhani B; Picheth G; Bouacida S; Bouaziz Z; Marminon C; Berredjem M; Jose J; Gonçalves MB; Ambudkar SV; Valdameri G; Le Borgne M
Sci Rep; 2021 Jan; 11(1):1788. PubMed ID: 33469044
[TBL] [Abstract][Full Text] [Related]
6. A new porphyrin as selective substrate-based inhibitor of breast cancer resistance protein (BCRP/ABCG2).
Zattoni IF; Kronenberger T; Kita DH; Guanaes LD; Guimarães MM; de Oliveira Prado L; Ziasch M; Vesga LC; Gomes de Moraes Rego F; Picheth G; Gonçalves MB; Noseda MD; Ducatti DRB; Poso A; Robey RW; Ambudkar SV; Moure VR; Gonçalves AG; Valdameri G
Chem Biol Interact; 2022 Jan; 351():109718. PubMed ID: 34717915
[TBL] [Abstract][Full Text] [Related]
7. Methoxy stilbenes as potent, specific, untransported, and noncytotoxic inhibitors of breast cancer resistance protein.
Valdameri G; Pereira Rangel L; Spatafora C; Guitton J; Gauthier C; Arnaud O; Ferreira-Pereira A; Falson P; Winnischofer SM; Rocha ME; Tringali C; Di Pietro A
ACS Chem Biol; 2012 Feb; 7(2):322-30. PubMed ID: 22039929
[TBL] [Abstract][Full Text] [Related]
8. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
Robey RW; Medina-Pérez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE
Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902
[TBL] [Abstract][Full Text] [Related]
10. Structural and molecular characterization of lopinavir and ivermectin as breast cancer resistance protein (BCRP/ABCG2) inhibitors.
Dutra JP; Scheiffer G; Kronenberger T; Gomes LJC; Zanzarini I; Dos Santos KK; Tonduru AK; Poso A; Rego FGM; Picheth G; Valdameri G; Moure VR
EXCLI J; 2023; 22():1155-1172. PubMed ID: 38204967
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of honokiol, magnolol and of a library of new nitrogenated neolignans as pancreatic lipase inhibitors.
Sciacca C; Cardullo N; Pulvirenti L; Di Francesco A; Muccilli V
Bioorg Chem; 2023 May; 134():106455. PubMed ID: 36913880
[TBL] [Abstract][Full Text] [Related]
12. Reaction with ROO• and HOO• Radicals of Honokiol-Related Neolignan Antioxidants.
Cardullo N; Monti F; Muccilli V; Amorati R; Baschieri A
Molecules; 2023 Jan; 28(2):. PubMed ID: 36677790
[TBL] [Abstract][Full Text] [Related]
13. Synthesized Magnolol Derivatives Improve Anti-
Jin Y; Yang F; Zhang G; Yu Q; Wang G; Ling F; Liu T
Viruses; 2022 Jun; 14(7):. PubMed ID: 35891401
[No Abstract] [Full Text] [Related]
14. Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Zattoni IF; Delabio LC; Dutra JP; Kita DH; Scheiffer G; Hembecker M; Pereira GDS; Moure VR; Valdameri G
Eur J Med Chem; 2022 Jul; 237():114346. PubMed ID: 35483322
[TBL] [Abstract][Full Text] [Related]
15. Magnolol and Honokiol Inhibited the Function and Expression of BCRP with Mechanism Exploration.
Yu CP; Li PY; Chen SY; Lin SP; Hou YC
Molecules; 2021 Dec; 26(23):. PubMed ID: 34885972
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
